Category

News
Myeloma is a complicated cancer type that can be tough to find a treatment option for which patients will respond to. However, in the past several months therapeutic options for patients with relapsed/refractory multiple myeloma have taken major steps forward. This in part due to new data from multiple trials including the phase III COLUMBA...
Continue Reading
The Government has today unveiled plans to establish a national cancer agency, which will be led directly by experts of the deadly disease, and a $60 million injection into Pharmac. Until today, decisions about how to tackle New Zealand’s cancer “crisis” came from bureaucrats within the Ministry of Health. By December 1, the Government has...
Continue Reading
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international team, led out of the Institute of Cancer Research in London, examined diagnosis, birth and death records of more than 150,000 people with all types of blood cancer — such as leukaemia, lymphoma or myeloma...
Continue Reading
According to findings from a study published in Cancer on the utilization of specific supportive care measures in older patients with multiple myeloma, only approximately two-thirds of patients received guideline-concordant administration of a bone-modifying agent. The course of treatment for patients with multiple myeloma is typically characterized by the administration of multiple lines of therapy associated with periods...
Continue Reading
A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has been successful, the company said Friday. The London-based drugmaker said it had positive headline results from the DREAMM-2 study of GSK2857916 (belantamab mafodotin), an antibody-drug conjugate that targets the antigen BCMA. It did not provide details of the data, but said...
Continue Reading
A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed or refractory multiple myeloma, according to results of a single-center, single-arm phase 2 clinical trial published in The Lancet Haematology. The dual CAR T-cell combination resulted in a 95% response rate, with 43% of patients achieving...
Continue Reading
This story was originally published on Stuff “Why does New Zealand need to reinvent the wheel?” Posed by National MP Maggie Barry, that was the question at the heart of a fight to have dozens of life-extending – and life-saving – drugs funded. Emotions ran high during Wednesday’s health select committee as plea after plea...
Continue Reading
This story was originally published on RNZ Politicians heard emotional pleas today from cancer survivors, people with disabilities and health agencies to boost Pharmac’s funding for life saving drugs. Petitions were presented to the Health Select Committee at Parliament – calling on medicines to be funded – including for breast, lung, ovarian cancers, along with...
Continue Reading
Dr Ken Romeril, chief executive, Myeloma New Zealand, is appearing today before the Health Select Committee in support of their submission asking for funding of six life-extending treatments for multiple myeloma patients. Dr Romeril said there have been huge advances in myeloma treatment internationally, but no new anti-myeloma medicines have been funded in NZ in...
Continue Reading
Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma. As more therapies become available, more thought will have to be put into determining how best to sequence agents. In the relapsed setting, that will be the most important...
Continue Reading
1 2 3 4 5 20

Floor 7, 90 The Terrace
Wellington Central
New Zealand